Royalty Pharma plc (RPRX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Pablo Legorreta.
RPRX tiene fecha de IPO 2020-06-16, 75 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $20.92B.
Royalty Pharma plc is a biopharmaceutical royalty company that identifies, evaluates, and acquires royalty streams from innovative drug therapies across the United States. The company collaborates with academic institutions, research hospitals, biotechnology companies, and pharmaceutical firms to fund biopharmaceutical innovation. Its diversified portfolio includes royalties on approximately 35 marketed therapies and 10 development-stage product candidates spanning therapeutic areas such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. Founded in 1996 and headquartered in New York, Royalty Pharma generates revenue through its ownership of royalty interests in marketed drugs while supporting the advancement of new treatments.
